Skip to main content

View full-text article in PMC

. 2021 Sep 29;6(1):7–16. doi: 10.1002/ags3.12514

TABLE 1.

Survival outcome from randomized controlled trials with adjuvant therapy for PDAC after surgical resection

Trial	Country	Treatment arms	Median OS (mo)	HR	P value	5‐y OS (%)
ESPAC‐1	Europe	5 FU + Folinic acid	19.7	0.66	.005	21.1
ESPAC‐1	Europe	Surgery alone	14	0.66	.005	8
CONKO‐001	Germany and Austria	Gemcitabine	22.8	0.76	.01	20.7
CONKO‐001	Germany and Austria	Surgery alone	20.2	0.76	.01	10.4
ESPAC‐3	Europe	5 FU + Folinic acid	23.1	0.94	.39	15.9
ESPAC‐3	Europe	Gemcitabine	23.6	0.94	.39	17.5
JASPAC‐01	Japan	S‐1 prodrug	46.5	0.57	<.001	44.1
JASPAC‐01	Japan	Gemcitabine	25.5	0.57	<.001	24.4
PRODIGE 24	France and Canada	mFOLFIRINOX	54.5	0.64	.003	63.4 ^a
PRODIGE 24	France and Canada	Gemcitabine	35	0.64	.003	48.6 ^a
APACT	North America, Europe, Australia	nab‐Paclitaxel + Gemcitabine	40.5	0.82	.0045	—
APACT	North America, Europe, Australia	Gemcitabine	36.2	0.82	.0045	—

Abbreviations: HR, hazard ratio; OS, overall survival.

^{^a}

3‐y OS (%).